Tag - LOGC

Developments

LogicBio gets FDA fast track designation for methylmalonic acidemia

LogicBio Therapeutics’ (NASDAQ:LOGC) LB-001 received FDA fast track designation for the treatment of methylmalonic acidemia (MMA). MMA is caused by a mutation in genes responsible for the breakdown of certain proteins...

November 4, 2020

Executive Moves

LogicBio names Mariana Nacht as CSO; Kyle Chiang as COO

LogicBio Therapeutics (NASDAQ:LOGC) appointed Mariana Nacht, Ph.D., as CSO, effective Nov. 30; and promoted Kyle Chiang, Ph.D., to the role of COO, effective Nov. 2. The company is expanding its leadership team to...

November 3, 2020

Developments

LogicBio’s methylmalonic acidemia candidate gets FDA orphan drug designation

LogicBio Therapeutics’ (NASDAQ:LOGC) investigational pediatric genome editing therapy, LB-001, received FDA orphan drug designation for the treatment of methylmalonic acidemia (MMA). MMA, a rare disease caused by...

April 30, 2019

Tag - LOGC

LogicBio gets FDA fast track designation for methylmalonic acidemia

LogicBio names Mariana Nacht as CSO; Kyle Chiang as COO

LogicBio’s methylmalonic acidemia candidate gets FDA orphan drug designation

General

More